Related references
Note: Only part of the references are listed.Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
Nut Koonrungsesomboon et al.
BMC CANCER (2020)
Secondary spontaneous pneumothorax in cancer patients
Horiana B. Grosu et al.
JOURNAL OF THORACIC DISEASE (2019)
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud et al.
LANCET ONCOLOGY (2019)
Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
Lu Xie et al.
ONCOLOGIST (2019)
Novel targeted therapies and immunotherapy for advanced thyroid cancers
George E. Naoum et al.
MOLECULAR CANCER (2018)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
The Major Causes of Death in Children and Adolescents in the United States
Rebecca M. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
Natacha Omer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Anti-angiogenesis target therapy for advanced osteosarcoma
Lu Xie et al.
ONCOLOGY REPORTS (2017)
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
Joanne P. Lagmay et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors
Rodrigo B. Interiano et al.
JOURNAL OF PEDIATRIC SURGERY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Gary L. Francis et al.
THYROID (2015)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
Arie J. Verschoor et al.
CLINICAL SARCOMA RESEARCH (2014)
Perspectives on cancer stem cells in osteosarcoma
Upal Basu-Roy et al.
CANCER LETTERS (2013)
Spontaneous Pneumothorax in Children with Osteosarcoma: Report of Three Cases and Review of the Literature
M. Fayda et al.
ACTA CHIRURGICA BELGICA (2012)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Pacini et al.
ANNALS OF ONCOLOGY (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Gene expression profiling of human sarcomas: Insights into sarcoma biology
K Baird et al.
CANCER RESEARCH (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma
I Sulzbacher et al.
MODERN PATHOLOGY (2003)
Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma
I Sulzbacher et al.
MODERN PATHOLOGY (2000)
Share Paper
